Literature DB >> 30241864

A pectin from fruits of Lycium barbarum L. decreases β-amyloid peptide production through modulating APP processing.

Lishuang Zhou1, Wenfeng Liao2, Hui Zeng2, Yanli Yao2, Xia Chen2, Kan Ding3.   

Abstract

Here, a pectin LBP1C-2 with the molecular weight of 99.8 kDa was purified from fruits of Lycium barbarum L. Its structure was elucidated as a backbone of alternate 1, 2-linked α-Rhap and 1, 4-linked α-GalpA, with branches of terminal (T) -, 1, 3-, 1, 6- and 1, 3, 6-linked β-Galp, T-, 1, 5- and 1, 3, 5-linked α-Araf and T-linked β-Rhap substituted at C-4 of 1, 2, 4-linked α-Rhap. The cell-based experiments indicated that LBP1C-2 suppressed Aβ42 production in a dose-dependent manner with no cytotoxicity. Further study showed that expression of β-site APP cleaving enzyme 1 (BACE1) was attenuated by LBP1C-2, while expression of ADAM10 was up-regulated by LBP1C-2. Moreover, LBP1C-2 promoted the expression of insulin-degradation enzyme (IDE). These results suggested that LBP1C-2 might be a leading compound for anti-Alzheimer's disease therapy by decreasing Aβ42 production through mediating BACE1 and ADAM10 as well as IDE expression.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid precursor protein processing; Aβ(42); Lycium barbarum L.; Pectin

Mesh:

Substances:

Year:  2018        PMID: 30241864     DOI: 10.1016/j.carbpol.2018.08.050

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  2 in total

1.  Wolfberry genomes and the evolution of Lycium (Solanaceae).

Authors:  You-Long Cao; Yan-Long Li; Yun-Fang Fan; Zhen Li; Kouki Yoshida; Jie-Yu Wang; Xiao-Kai Ma; Ning Wang; Nobutaka Mitsuda; Toshihisa Kotake; Takeshi Ishimizu; Kun-Chan Tsai; Shan-Ce Niu; Diyang Zhang; Wei-Hong Sun; Qing Luo; Jian-Hua Zhao; Yue Yin; Bo Zhang; Jun-Yi Wang; Ken Qin; Wei An; Jun He; Guo-Li Dai; Ya-Jun Wang; Zhi-Gang Shi; En-Ning Jiao; Peng-Ju Wu; Xuedie Liu; Bin Liu; Xing-Yu Liao; Yu-Ting Jiang; Xia Yu; Yang Hao; Xin-Yu Xu; Shuang-Quan Zou; Ming-He Li; Yu-Yun Hsiao; Yu-Fu Lin; Chieh-Kai Liang; You-Yi Chen; Wan-Lin Wu; Hsiang-Chai Lu; Si-Ren Lan; Zhi-Wen Wang; Xiang Zhao; Wen-Ying Zhong; Chuan-Ming Yeh; Wen-Chieh Tsai; Yves Van de Peer; Zhong-Jian Liu
Journal:  Commun Biol       Date:  2021-06-03

Review 2.  Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment.

Authors:  Chujun Deng; Huize Chen; Zeyu Meng; Shengxi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-21       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.